AI Analysis Reveals Menopausal Hair Loss Linked to Systemic Health and Inflammation

A new AI-enabled analysis of 187,016 menopausal women on the MDhair.co platform suggests that women presenting with menopausal hair loss are not simply older versions of the general female population.¹ Instead, they carry a measurably higher burden of thyroid disease, gastrointestinal symptoms, scalp inflammation, and family history of hair loss than US women of the same age. The findings argue for an integrated diagnostic workup in menopausal female pattern hair loss (FPHL), rather than treatment focused on hormones and topicals alone.

The study, presented last month at the 14th World Congress for Hair Research in Seoul, Korea, was led by Yoram Harth, MD, FAAD, co-founder of MDalgorithms, and co-author Oded Harth. The authors describe it as the largest menopausal hair loss cohort reported to date.

Study Cohort and Methods

Cross-sectional, self-reported data were collected from 187,016 menopausal women using the MDhair.co AI-based platform. The cohort was predominantly aged 45 to 64 years (91.2%), with 8.8% aged 65 or older. The team analyzed hair loss severity, onset pattern, family history, scalp symptoms, thyroid dysfunction, COVID-19 history, digestive issues, and diet.

Data acquisition and analysis were powered by MDalgorithms’ proprietary AI engine that combines computer-vision scoring of user-submitted scalp and skin images with standardized symptom, comorbidity, and lifestyle questionnaires to generate a uniform, machine-readable phenotype for each user. Throughout the analysis, the authors compared the cohort to published US epidemiologic estimates for women in the same age range to characterize how a treatment-seeking menopausal hair loss population differs from the general population.

Hair Loss Onset and Severity Trends

Mild thinning was reported by 43.2% of participants, moderate by 38.1%, and severe by 12.8%—a combined moderate-to-severe rate of 51.0%. Onset was gradual in 55.6% of women and sudden in 20.4%. Severe thinning was nearly twice as common in women 65 and older as in those 45 to 64 (20.3% vs 12.1%; χ²=2,032.5, P < .001).

Published population-based estimates put clinically detectable FPHL at roughly 25% of women by age 49 and about 40 to 41% by age 69, with classic dermatology cohorts (Norwood; Birch et al.) reporting moderate-to-severe thinning in approximately 30 to 38% of women aged 45 to 64.² The 51.0% moderate to severe rate in the MDhair cohort is therefore meaningfully higher than general-population baselines, consistent with a self-selected, treatment-seeking sample. The authors treat this enrichment not as a confound but as a defining feature: this is the half of the menopausal population in whom hair loss is clinically meaningful and modifiable.

The Role of Genetic Loading and Susceptibility

A positive family history of hair loss was reported by 26.6% of the cohort overall, and was strongly predictive of disease severity: 61.3% of women with a family history reported moderate-to-severe thinning, compared with 45.8% of those without (χ²=3,694.2, P < .001). Genetic susceptibility was, as expected, over-represented relative to the unselected female population, in which familial FPHL is reported in roughly 15–20% of women, underscoring that the women presenting for treatment carry both a heavier symptomatic and a heavier genetic load.

MORE ON HAIR LOSS

Scalp Inflammation and Chronic Pruritus As Severity Signals

Chronic scalp pruritus emerged as one of the strongest severity signals. Women reporting constant scalp itch had a 2.2-fold higher rate of severe thinning than those who never itched (22.7% vs 10.4%; χ²=1,808.8, P < .001). Dry or flaky scalp was reported by 20.5% of participants and was also significantly associated with severity. By comparison, population-based studies of chronic pruritus put 12-month prevalence in the general adult population at roughly 13 to 17%, with scalp-specific itch in a similar range. The MDhair cohort’s combined often/always itch rate was approximately double that of the baseline.

“The 2.2-fold increased risk of severe thinning in women reporting constant scalp itchiness points to a potentially important inflammatory component that merits further study,” Harth told Dermatology Times. “In menopausal hair loss, we should be treating the scalp as actively as we treat the follicle.”

Systemic Health Comorbidities

Thyroid dysfunction was reported by 19.4% of women overall and 27.4% of those aged 65 and older (χ²=211.2, P < .001). US epidemiologic data put overall thyroid dysfunction in women aged 45 to 64 at roughly 10 to 14%, and subclinical hypothyroidism in women over 60 at about 15%. Rates of clinically reported thyroid disease in this cohort therefore run roughly 1.5–2× the general-population estimate—a magnitude consistent with thyroid dysfunction being a true, under-recognized driver of menopausal FPHL severity rather than a chance association.

Digestive issues were reported by nearly 1 in 3 women (32.6%). Population estimates of irritable bowel syndrome and chronic functional GI disorders in US women aged 45 to 64 cluster around 10 to 15%, so the cohort rate is approximately 2–3× background. Low vegetable intake was also significantly associated with hair loss severity (P < .001). Together, these point to nutrient absorption and gut–scalp axis hypotheses that warrant prospective study, according to the authors.

A history of COVID-19 was significantly associated with sudden shedding (26.0% vs 18.8%; χ²=736.5, P < .001). Self-reported prior COVID-19 in this cohort (~20–26%) is well below CDC infection-induced seroprevalence estimates, which exceeded 75% of U.S. adults by 2023. The COVID–shedding signal observed here is almost certainly conservative, and the true post-viral telogen effluvium contribution to menopausal hair loss may be larger than the χ² suggests.

Clinical Implications

Taken together, the comparison to age-matched general-population data reframes the cohort. Women presenting with menopausal hair loss are roughly 2× as likely to have thyroid disease, 2–3× as likely to report chronic GI symptoms, and roughly 2× as likely to have inflammatory scalp symptoms as their peers. Family history is over-represented. COVID-19 history is under-reported, but still tracks with sudden shedding.

“Hair loss in menopausal women is not a single disease—and it is not just a hair problem,” Harth said. “It is the visible end of a broader inflammatory, endocrine, and gastrointestinal phenotype. A workup that screens for thyroid dysfunction, gut symptoms, scalp inflammation, and post-viral exposure will catch drivers that purely hormonal or topical treatment paradigms miss.”

The authors argue that these findings support an integrated management model that addresses scalp inflammation, thyroid and metabolic health, nutrition, post-viral status, and genetic predisposition alongside hormonal and topical therapies—and that digital, AI-based platforms are uniquely positioned to surface these signals at population scale. According to Harth, longitudinal follow-up and image-based scalp diagnostics are the next steps.

References

1. Harth Y, Harth O. Multi-factorial determinants of hair loss severity and progression in menopausal women: a large-scale analysis of 187,016 cases. Poster presented at: 14th World Congress for Hair Research; May 28–31, 2026; COEX, Seoul, Korea. Abstract E-466.

2. Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg. 2001;27(1):53-54.